A global study led by the University of Colorado Cancer Center, published in Blood Cancer Discovery, reveals that both genetic mutations and leukemia cell maturity determine how patients respond to AML treatment with venetoclax and hypomethylating agents. Lead researcher Daniel Pollyea, MD, says the findings move the field closer to personalized medicine, helping doctors match patients with therapies most likely to succeed.